Heart & Vascular Care Backed by Innovative Research
For more than 20 years, WellSpan's Heart and Vascular Research Department, along with Wellspan Cardiology, Cardiac Surgery and Vascular Surgery, actively participate in clinical trials offered in the United States and Globally.
Our physicians also develop and conduct their own research exclusively for WellSpan patients. These research projects are supported by the Heart and Vascular Research Department from the early development stages through study completion, they conducted in the same ethical and safety standards as our large clinical trials.
To learn more about our Heart and Vascular Clinical trials, call us at (717) 851-4049.
How We Can Help
Researchers are identifying the newest and most effective treatment methods for cardiovascular disease through these carefully designed and conducted clinical trials. These advances help patients to live longer and better lives.
We are currently enrolling patients in the following trials. The NCT# specific identifying number assigned to a research trail when it is registered at the clinicaltrials.gov website. Learn more about these trials at ClinicalTrials.gov.
Wait times are the length of time between when a patient checks in and when the patient is taken to the treatment room.
The values shown are the median, or the middle number in the set of all the wait times collected for the previous 15 minutes.
Wait times can be influenced by many factors and should be considered estimates only.
WellSpan York Hospital
DRUG STUDIES
NODE-303: A Phase 3, Multi-Center, Multi-National, Open Label, Safety Study of Etripamil Nasal Spray for Patients with Paroxysmal Supraventricular Tachycardia. [NCT #04072835]
Sponsor: Milestone Pharmaceuticals
Principal Investigator: Gregory Fazio, MD
The primary objective is to evaluate the safety of self-administered Etripamil nasal spray (NS) outside of the clinical setting for patients with a diagnosis of Paroxysmal Supraventricular Tachycardia
ORION HPS-4/TIMI 65/ORION-4: A Phase 3, double-blind randomized placebo-controlled trial assessing the effects of inclisiran on clinical outcomes among people with atherosclerotic cardiovascular disease. [NCT #03705234]
Sponsor: University of Oxford
Principal Investigator: Kevin McCullum, MD
Testing whether a medicine called Inclisiran, which is given by subcutaneous injection every six months, can safely help to prevent heart attacks and strokes in patients who are known to have diseased arteries.
DAPA ACT HF-TI MI 68: A Phase 3b/4, Multicenter, Randomized, Double-Blind, Parallel Group, Placebo- Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure Dapagliflozin and Effect on Cardiovascular Events in Acute Heart Failure - Thrombolysis in Myocardial Infarction 68. [NCT #04363697] *Currently eligible to hospitalized patients only
Sponsor: TIMI Study Group
Principal Investigator: Adnan Malik, MD, FACC
Primary objective is to assess the effect of in-hospital initiation of Dapagliflozin, as compared with placebo, on the clinical outcome of cardiovascular death or worsening heart failure in patients who have been stabilized during hospitalization for acute heart failure.
DEVICE STUDIES
ACURATE IDE: Transcatheter Replacement of Stenotic Aortic Valve through Implantation of ACURATE in Subjects InDicatEd for TAVR. [NCT #03735667]
Sponsor: Boston Scientific
Principal Investigator: James Harvey, MD, FACC
Study objective to evaluate safety and effectiveness of the ACURATEneo2TM Transfemoral Aortic Valve System for transcatheter aortic valve replacement (TAVR) in subjects with severe native aortic stenosis who are indicated for TAVR.
CATALYST: Clinical trial of atrial fibrillation patients comparing left atrial appendage occlusion therapy to non-vitamin K antagonist oral anticoagulants. [NCT #04226547]
Sponsor: ABBOTT
Principal Investigator: Brian Schuler, MD
The objective of this trial is to evaluate the safety and effectiveness of the Amulet device compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy.
CHAMPION-AF: WATCHMAN FLX versus NOAC for EMbolic ProtectION in the Management of Patients with Non-Valvular Atrial Fibrillation. [NCT #04394546]
Sponsor: Boston Scientific
Principal Investigator: Brian Schuler, MD
The primary objective of this study is to determine if left atrial appendage closure with the WATCHMAN FLX device is a reasonable alternative to non-vitamin K oral anticoagulants (NOACs) in patients with non-valvular atrial fibrillation.
TAVR-UNLOAD: Transcatheter Aortic Valve Replacement to UNload the Left ventricle in patients with Advanced heart failure: (TAVR UNLOAD). [NCT #02661451]
Principal Investigator: James Harvey, MD, FACC
The objective of this study is to determine the safety and efficacy of transcatheter aortic valve replacement (TAVR) via a transfemoral approach in HF patients with moderate AS as compared with OHFT.
REGISTRY
PROGRESS CTO: Multicenter Registry of Chronic Total Occlusion Interventions. [NCT #02061436]
Principal Investigator: Stewart Benton Jr, MD, FACC
Real- AF: Real-world Experience of Catheter Ablation from the treatment of Paroxysmal and Persistent Atrial Fibrillation using novel contact force technologies (REAL-AF) [NCT #04088071]
Sponsor: Heart Rhythm Clinical and Research Solutions, LLC (HRCRS)
Principal Investigator: Matthew Singleton, MD
STAR: To date, there have been no studies that prospectively and systemically evaluated the efficacy and safety of STAR with deferred stenting and described the frequency of its use in the hybrid approach. The aim of this study is to address these current gaps in knowledge, including the frequency of use of STAR by experienced operators, the safety of its use, optimal timing of staged stenting and health status change associated with this procedure. This prospective study will enroll 150 patients undergoing elective PCI of native CTO utilizing the STAR technique and will subsequently randomize patients in a 1:1 fashion to early (5-7 weeks) and later (12-14 weeks) timing of subsequent stenting. [NCT05089864]
Sponsor: Saint Luke’s Hospital of Kansas City
Principal Investigator: Dr Rhian Davies
